Skip Navigation
Find a Doctor


Photo of Dr. Ross Donehower

Ross C Donehower, MD

Director, Medical Oncology/Hematogy Fellowship Training Program
Professor of Oncology
Appointment Phone


Main Location

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

View All Locations
Out-of-State & International Patients +
Out of State Patients

Call 410-464-6641 (8a.m. to 6p.m., EST, Mon-Fri)

Learn more about our out-of-state patient services »

International Patients

Call +1-410-502-7683 (7a.m. to 6p.m., EST, Mon-Fri)

Learn more about our international patient services »


  • Director, Medical Oncology/Hematogy Fellowship Training Program
  • Director, Division of Medical Oncology
  • Professor of Oncology
  • Professor of Medicine

Centers & Institutes

  • Sidney Kimmel Comprehensive Cancer Center
  • Skip Viragh Center for Pancreas Cancer Clinical Research and Patient Care


Anal Cancer, Bile Duct Cancer, Carcinoid Syndrome, Carcinoid Tumors, Cholangiocarcinoma, Clinical Trials, Colon Cancer, Colorectal Cancer, Gastric Cancer, Gastroesophageal Junction Cancer, Gastrointestinal Cancers, Gastrointestinal Tumors, Hepatocellular Cancer, Liver Cancer, Medical Oncology, Neuroendocrine Tumors, Pancreatic Cancer, Rectal Cancer, Small Bowel Cancer, Small Intestine Cancer, Stomach Cancer

Research Interests

Gastrointestinal Cancers ; New Anticancer Drug Development ; Pharmacology


  • English
Additional Resources +
  • Education +


    • University of Minnesota Medical School (Minneapolis MN ) (1974)


    • Johns Hopkins University School of Medicine / Medicine (Baltimore MD ) (1976)


    • National Cancer Institute - NIH / Medical Oncology (Bethesda MD ) (1980)


    • Medical Oncology, American Board of Internal Medicine (1979)
    • Internal Medicine, American Board of Internal Medicine (1977)
  • Research & Publications +

    Selected Publications

    Gilbert, J.; Carducci, M.A.; Baker, S.D.; Dees, E.C.; Donehower, R. A Phase I study of the oral antimetabolite, CS-682, administered once daily 5 days per week in patients with refractory solid tumor malignancies. Invest New Drugs. 2006 Nov;24(6):499-508.

    Messersmith, W.A.; Baker, S.D.; Lassiter, L.; Sullivan, R.A.; Dinh, K.; Almuete, V.I.; Wright, J.J.; Donehower, R.C.; Carducci, M.A.; Armstrong, D.K. Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors. Clin Cancer Res. 2006 Feb 15;12(4):1270-1275.

    Sommer, M.; Poliak, N.; Upadhyay, S.; Ratovitski, E.; Nelkin, B.D.; Donehower, L.A.; Sidransky, D. DeltaNp63alpha overexpression induces downregulation of Sirt1 and an accelerated aging phenotype in the mouse. Cell Cycle. 2006 Sep;5(17):2005-2011.

    Blakeley, J.; Laterra, J. Neurotoxicities. In: Ettinger, D.S.; Donehower, R., editors, Current Cancer in Therapeutics: Springer; 2007.

    Dunbar, E.; Laterra, J. Malignant glioma. In: Ettinger, D.S.; Donehower, R., editors: Current Cancer Therapeutics; 2007. p. In press.

    Li, J.; Zhao, M.; Jimeno, A.; He, P.; Ramana Reddy, M.V.; Hidalgo, M.; Donehower, R.C.; Rudek, M.A. Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate ON 01910.Na, a mitotic progression modulator, in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Sep 1;856(1-2):198-204.

    Messersmith, W.A.; Rudek, M.A.; Baker, S.D.; Zhao, M.; Collins, C.; Colevas, A.D.; Donehower, R.C.; Carducci, M.A.; Wolff, A.C. Phase I study of continuous weekly dosing of dimethylamino benzoylphenylurea (BPU) in patients with solid tumours. Eur J Cancer. 2007 Jan;43(1):78-86.

    Brahmer, J.R. Lung Cancer. In: Donehower, R.; Ettinger, D., editors. 5th Edition ed, Current Cancer Therapeutics. New York, NY: Churchill-Livingstone; 2008.

    Brandes, J.C.; Yung, R.C. Pulmonary and Cardiovascular Complications of Cancer Therapy. In: Ettinger, D.; Donehower, R., editors, Current Cancer Therapeutics, Fifth Edition: Current Medicine, LLC; 2008.

    Herman, J.M.; Swartz, M.J.; Hsu, C.C.; Winter, J.; Pawlik, T.M.; Sugar, E.; Robinson, R.; Laheru, D.A.; Jaffee, E.; Hruban, R.H.; Campbell, K.A.; Wolfgang, C.L.; Asrari, F.; Donehower, R.; Hidalgo, M.; Diaz, L.A., Jr.; Yeo, C.; Cameron, J.L.; Schulick, R.D.; Abrams, R. Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol. 2008 Jul 20;26(21):3503-3510.

    Jimeno, A.; Li, J.; Messersmith, W.A.; Laheru, D.; Rudek, M.A.; Maniar, M.; Hidalgo, M.; Baker, S.D.; Donehower, R.C. Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors. J Clin Oncol. 2008 Dec 1;26(34):5504-5510.

    Jimeno, A.; Messersmith, W.A.; Lee, C.K.; Ma, W.W.; Laheru, D.; Donehower, R.C.; Baker, S.D.; Hidalgo, M. Phase I study of troxacitabine administered by continuous infusion in subjects with advanced solid malignancies. Ann Oncol. 2008 Feb;19(2):374-379.

    Jimeno, A.; Rudek, M.A.; Kulesza, P.; Ma, W.W.; Wheelhouse, J.; Howard, A.; Khan, Y.; Zhao, M.; Jacene, H.; Messersmith, W.A.; Laheru, D.; Donehower, R.C.; Garrett-Mayer, E.; Baker, S.D.; Hidalgo, M. Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors. J Clin Oncol. 2008 Sep 1;26(25):4172-4179.

    Jimeno, A.; Rudek, M.A.; Purcell, T.; Laheru, D.A.; Messersmith, W.A.; Dancey, J.; Carducci, M.A.; Baker, S.D.; Hidalgo, M.; Donehower, R.C. Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors. Cancer Chemother Pharmacol. 2008 Mar;61(3):423-433.

    Laheru, D.; Croghan, G.; Bukowski, R.; Rudek, M.; Messersmith, W.; Erlichman, C.; Pelley, R.; Jimeno, A.; Donehower, R.; Boni, J.; Abbas, R.; Martins, P.; Zacharchuk, C.; Hidalgo, M. A phase I study of EKB-569 in combination with capecitabine in patients with advanced colorectal cancer. Clin Cancer Res. 2008 Sep 1;14(17):5602-5609.

    Le, D.; Kim, P.; Jaffee, E.M. Current Cancer Therapeutics. In: David Ettinger, R.D., editor, Cancer Vaccines. Philadelphia: Current Medicine, LLC; 2008.

    Messersmith, W.A.; Jimeno, A.; Ettinger, D.; Laheru, D.; Brahmer, J.; Lansey, D.; Khan, Y.; Donehower, R.C.; Elsayed, Y.; Zannikos, P.; Hidalgo, M. Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2008 Dec;63(1):181-188.

    Jimeno, A.; Chan, A.; Cusatis, G.; Zhang, X.; Wheelhouse, J.; Solomon, A.; Chan, F.; Zhao, M.; Cosenza, S.C.; Ramana Reddy, M.V.; Rudek, M.A.; Kulesza, P.; Donehower, R.C.; Reddy, E.P.; Hidalgo, M. Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay. Oncogene. 2009 Jan 29;28(4):610-618.

    Lin, J.; Gilbert, J.; Rudek, M.A.; Zwiebel, J.A.; Gore, S.; Jiemjit, A.; Zhao, M.; Baker, S.D.; Ambinder, R.F.; Herman, J.G.; Donehower, R.C.; Carducci, M.A. A phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumors. Clin Cancer Res. 2009 Oct 1;15(19):6241-6249.

    Garrido-Laguna, I.; Tan, A.C.; Uson, M.; Angenendt, M.; Ma, W.W.; Villaroel, M.C.; Zhao, M.; Rajeshkumar, N.V.; Jimeno, A.; Donehower, R.; Iacobuzio-Donahue, C.; Barrett, M.; Rudek, M.A.; Rubio-Viqueira, B.; Laheru, D.; Hidalgo, M. Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer. Br J Cancer. 2010 Aug 24;103(5):649-655.
    Husain, H.; Cosgrove, D.; Donehower, R. Adenocarcinoma of Unknown Primary. In: Group, B., editor. Vol. Online Database-Not Supported Through NIH Funding, BMJ Point of Care: BMJ Group; 2010.

    Lin, J.; Donehower, R.C. Make quality cancer survivorship care possible in the era of workforce shortage. J Oncol Pract. 2010 Jan;6(1):52-53.

    Ma, W.W.; Herman, J.M.; Jimeno, A.; Laheru, D.; Messersmith, W.A.; Wolfgang, C.L.; Cameron, J.L.; Pawlik, T.M.; Donehower, R.C.; Rudek, M.A.; Hidalgo, M. A tolerability and pharmacokinetic study of adjuvant erlotinib and capecitabine with concurrent radiation in resected pancreatic cancer. Transl Oncol. 2010;3(6):373-379.

    Messersmith, W.A.; Jimeno, A.; Jacene, H.; Zhao, M.; Kulesza, P.; Laheru, D.A.; Kahn, Y.; Spira, A.; Dancey, J.; Iacobuzio-Donahue, C.; Donehower, R.C.; Carducci, M.; Rudek, M.A.; Hidalgo, M. Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer. Clin Colorectal Cancer. 2010 Dec;9(5):297-304.

    Weekes, C.D.; Nallapareddy, S.; Rudek, M.A.; Norris-Kirby, A.; Laheru, D.; Jimeno, A.; Donehower, R.C.; Murphy, K.M.; Hidalgo, M.; Baker, S.D.; Messersmith, W.A. Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer. Invest New Drugs. 2010 Mar 23.

    Villarroel, M.C.; Rajeshkumar, N.V.; Garrido-Laguna, I.; De Jesus-Acosta, A.; Jones, S.; Maitra, A.; Hruban, R.H.; Eshleman, J.R.; Klein, A.; Laheru, D.; Donehower, R.; Hidalgo, M. Personalizing Cancer Treatment in the Age of Global Genomic Analyses: PALB2 Gene Mutations and the Response to DNA Damaging Agents in Pancreatic Cancer. Mol Cancer Ther. 2011 Jan;10(1):3-8.
  • Academic Affiliations & Courses +
  • Activities & Honors +
  • Videos & Media +
  • Events +
  • Contact & Locations +


    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
    401 N. Broadway
    Baltimore, MD 21231
    Appointment Phone: 410-955-8964
    Location Map
    Johns Hopkins Medicine - Green Spring Station
    10753 Falls Road
    Pavilion II
    Baltimore, MD 21093
    Appointment Phone: 410-583-2970
    Location Map


    • Oncology

Is This You? Edit Profile


© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.